News

Second-Line Cabozantinib Demonstrates Clinical Activity in Metastatic Renal Cell Carcinoma

08/31/2022

Allison Casey

Cabozantinib demonstrates meaningful clinical activity as a second-line treatment for patients with metastatic renal cell carcinoma, irrespective of prior exposure to VEGF inhibitors.

Cabozantinib demonstrates...

08/31/2022

Oncology

News

Prognostic Impact of Statin Use Among Patients With Renal Cell Carcinoma Receiving Nivolumab

08/22/2022

Allison Casey

Study findings reveal statin use improves the efficacy of nivolumab among patients with metastatic renal cell carcinoma.

Study findings reveal statin use...

08/22/2022

Oncology

News

Telaglenastat Plus Everolimus Improves PFS vs Placebo Plus Everolimus in Metastatic Renal Cell Carcinoma

07/29/2022

Allison Casey

Findings from a phase 2 trial show telaglenastat plus everolimus is well-tolerated and improves PFS vs placebo and everolimus among patients with metastatic renal cell carcinoma who had received prior treatment with TKIs and checkpoint...

Findings from a phase 2 trial...

07/29/2022

Oncology

News

Immune Checkpoint Inhibitors May Improve Survival Among Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

07/07/2022

Allison Casey

For patients with advanced non-clear cell renal cell carcinoma, immune checkpoint inhibitors in the first line appeared to be associated with improved overall survival when compared to vascular endothelial growth factor and mammalian target...

For patients with advanced...

07/07/2022

Oncology

News

Nivolumab Plus Ipilimumab Superior to Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma

06/13/2022

John Otrompke

Nivolumab plus ipilimumab demonstrated durable clinical benefit over sunitinib for the first-line treatment of patients with advanced renal cell carcinoma after 5 years of follow-up, according to findings from the CheckMate 214 trial.

Nivolumab plus ipilimumab...

06/13/2022

Oncology

Conference Coverage

Perioperative Management of Clear Cell Renal Cell Carcinoma

03/30/2022

Janelle Bradley

In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Bradley McGregor, MD, gave an update on the perioperative management of clear cell renal cell carcinoma.

In a presentation at the 2022...

03/30/2022

Oncology

News

Pembrolizumab Yields Significantly Longer DFS Than Placebo in Renal Cell Carcinoma

09/24/2021

Pembrolizumab was associated with significantly longer disease-free survival in comparison to placebo in a phase 3 trial developed to reduce the high risk of recurrence in patients with renal cell carcinoma after nephrectomy.

Pembrolizumab was associated...

09/24/2021

Oncology

News

FDA Approves Tivozanib for R/R Advanced RCC

03/11/2021

The FDA has approved tivozanib for the treatment of certain pre-treated patients with relapsed/refractory advanced RCC.

The FDA has approved tivozanib...

03/11/2021

Oncology

News

First-Line Pembrolizumab Demonstrates Antitumor Activity in ccRCC Patients

03/01/2021

Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.

Pembrolizumab monotherapy as a...

03/01/2021

Oncology

News

Axitinib Yields Better Tumor Response Rate Over Nivolumab in mRCC

02/05/2021

Axitinib showed a better tumor response rate than nivolumab, according to a study comparing the 2 as second-line treatment in mRCC.

Axitinib showed a better tumor...

02/05/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology